Zoetis unveiled the Centre for Digital Innovation (CDI), it's new centre for creating digital products that enable data-driven decision-making to enhance precision farming and improve animal wellbeing for livestock and pets, at the House of Lords last week.
The company says its target is to create a digital health record for every UK livestock animal to enable data-driven decision-making and precision farming.
One of the first products in the pipeline is a device that provides real-time monitoring of growth and weight gain in a pig herd using non-intrusive visual imaging. It monitors actual growth against predicted growth, recording the number of daily visits to the water and feed station by individual animals. It produces a weight distribution graph and pinpoints both under and over achievers in the growth stakes, recording key dimensions and accurate measurements of the animal’s weight. Data from the device can be processed in seconds and uploaded into a web reporting tool.
Also in the pipeline is an app that can detect and monitor information on a cow's lameness.
Zoetis says it believes that advanced digital solutions could also significantly improve the wellbeing of companion animals. To that end, the company has built a new digital ecosystem for vets that includes a mobile app - PetDialog - to help better connect owners with their pet and vet. The PetDialog app features a Quality of Life assessment produced by NewMetrica from technology developed by the University of Glasgow. Using psychometric methodology, the assessment measures and monitors the quality of life of the dog so that the owner and vet can gain a deeper insight into the animal's health and wellbeing, including the early detection of health issues, managing disease and measuring the impact of treatment. Just as is the case in human medicine, the device will facilitate the remote monitoring of conditions such as blood glucose monitoring for diabetic cats and dogs.
Lord de Mauley, Science Minister, said: "I welcome this new investment which will add great value to UK capability in this area. It builds on the close relationship Zoetis already has with our universities and institutes including many Research and Development collaborations.
"Zoetis's decision to locate the Centre in the UK recognises the strength of our data sciences expertise and commitment to innovation including agricultural and biomedical science."
Ned Flaxman, CDI director (pictured right), said: "We believe that in this particular space, where technologies are advancing rapidly, the need for complimentary strategic partnerships is essential. Through our Alliances group we work actively in establishing the appropriate University and industry collaborations that will enable our CDI specialists to develop together the most comprehensive and valued digital solutions for our animals."
The Queen's Medal is the highest honour the College can bestow upon a veterinary surgeon.
Dr Johnson is the Chairman of World Horse Welfare, travelling internationally and lecturing on behalf of the charity with a particular involvement in fundraising, profile-enhancing and education. He is also the Chairman of the World Horse Welfare International Committee, and a regional representative for the Veterinary Benevolent Fund as well as being Deputy Lord Lieutenant for Lancashire.
After graduating from the University of Liverpool in 1969 he established an equine and farm animal practice in 1974 on the Fylde Coast. He then quickly became involved in many other lines of work, lecturing at the Myerscough College for thirty years, acting on the Agricultural Training Board, and serving as RCVS President from 1993-1994. He was also an RCVS Council Member for 28 years (1986-1998; 2000-2016) and served on many RCVS Committees.
Barry said: "This is an enormous honour for a practitioner from Lancashire. I have always enjoyed being a veterinary surgeon and am grateful to my colleagues and clients for making my career so fulfilling rewarding and fun."
He was nominated by fellow veterinary surgeon, Dr Peter Jinman, a current member of RCVS Council. In his nomination Dr Jinman said: "There are few members who have contributed so much of their personal time for the benefit of the veterinary profession both locally and nationally… That this has been done often without the knowledge of the public or the rest of the profession and at no little personal expense, demands recognition… Barry represents the very best of what a veterinary practitioner can achieve both in terms of his profession and in wider society."
The College has also announced that Kathy Kissick has won this year's Golden Jubilee Award, the highest honour that can be bestowed on a veterinary nurse.
Kathy is a trustee of the Alderney Animal Welfare Society and has previously acted as the Head of School for Veterinary Nursing and Farriery Science at Mysercough College in Lancashire. She qualified as a veterinary nurse in 1983 and, since then, has acted as an external examiner and adviser for a number of veterinary nursing course providers over the years and is currently on the editorial board for The Veterinary Nurse.
She has also been very active within the RCVS, initially as a nursing examiner and then as both a Member and then Chair of the RCVS Veterinary Nurses Council.
Kathy said: "I am delighted, honoured and humbled to accept the Golden Jubilee award and hope that I can continue to inspire veterinary nurses, throughout their careers, to always do the very best for their patients, clients and colleagues but not to forget to follow their dreams."
The winners will receive their accolade at this year’s RCVS Day, which takes place on Friday 7 July at the Royal Institute of British Architects.
Insistor, which contains methadone hydrochloride, is now available in the UK in a 10ml bottle for use in dogs and cats, POM-V.
Chanelle says Insistor can also be used for analgesia in animals experiencing post-operative pain or pain caused by trauma.
Chanelle’s Head of Sales and Marketing, Killian Gaffney, said: "Insistor joins Chanelle’s extensive anaesthetic, analgesic and sedative range. Insistor (methadone hydrochloride), Butador (butorphanol) and Bupaq (buprenorphone) complete the 360° Opiod suite of products from Chanelle.
"We are pleased to add Insistor to our portfolio of products, which builds the offering to veterinary surgeons of anaesthetic products."
Merck, part owner of Merial, has announced a merger with Intervet Schering-Plough.
However, rumours that Merck plans to sell its 50% stake in Merial and move forward with Intervet Schering Plough are incorrect, according to Merck spokespeople.
They'll have to start thinking about what to call themselves soon. Merial-Intervet-Schering-Plough is a bit of a mouthful.
TVM says Emedog provides less wastage, provides easier dosing and is a solution designed specifically for veterinary use.
Simon Boulton MRCVS, Marketing Manager at TVM said: "The use of apomorphine in practice is a vital first-line response when emesis is required due to the ingestion of unwanted substances.
However, 86% of vets questioned thought that wastage was an issue with Apometic and many thought that dosing was difficult in very small animals due to tiny volumes. The new solution is Emedog. Practitioners must be aware that the dose of Emedog is different to that of Apometic and use accordingly."
TVM have provided a dosing guide as part of a changeover pack to aid in the transition. For a copy, contact your local TVM territory manager, email them via help@tvm-uk.com, download from www.tvm-uk.com or ring 01737 781416.
Cytopoint is an injectable monoclonal antibody therapy for dogs that targets and neutralises the cytokine IL-31, a mediator of allergic itch1.
Zoetis says the new claim was granted following a randomised, double-masked, multi-centred, placebo-controlled study which looked at Cytopoint’s efficacy and safety for the treatment of pruritus associated with allergic dermatitis in client-owned dogs. The study showed that Cytopoint significantly decreased pruritus, and improved skin lesions.2
Allison Henry, Product Manager Companion Animal Dermatology at Zoetis UK, says: "Allergic dermatitis is one of the most common skin conditions in dogs.3 The associated clinical signs – including scratching, hair loss and skin lesions – are disruptive for the dog, impacting their quality of life and that of its owner. Allergic skin disease is one of the most frequent reasons owners present their dog to a veterinarian.
"The licence extension demonstrates further innovation from Zoetis in the field of veterinary dermatology, and across the continuum of care, increasing the treatment options available to manage pruritus. Apoquel remains an ideal choice for short-term control due to its ability to provide rapid itch relief within four hours4 for as little as one day.5 This enables pruritus to be tightly controlled during the diagnostic work up,7 as well as being used for longer term control where tablets are the preferred method of administration.
"The sustained duration of action of Cytopoint makes it better suited to long-term management of pruritus, particularly when administering tablets is a challenge. Other benefits, such as no restrictions on age or with comorbidities, coupled with the flexibility of the new claim, make it a useful treatment at an earlier stage for more unique cases, e.g. young dogs or those with comorbidities."
For further information, contact your Zoetis Account Manager.
watch?v=A8EJ8LpLVzw&feature=youtu.be
References
Eukanuba has published the results of a 10 year study to evaluate the health and longevity of continuously Eukanuba-fed dogs, in which 90% lived beyond the breed's typical lifespan.
Before the start of the study, a independent panel of veterinary academics and experts assessed existing evidence concerning the longevity of Labrador Retrievers and came to a consensual conclusion that the average lifespan for the breed is 12 years.
39 Labrador Retrievers in early to mid-adulthood were then enrolled in the study1, which began in 2004. All the dogs were neutered and had identical housing, standardised daily care and veterinary care. The dogs were fed the amount of food needed to maintain each dog within an optimal body condition score.
Remarkably, 28% of the dogs in the study achieved exceptional longevity, living beyond 15.6 years. One dog very nearly made it to 18 years of age.
The study was overseen Eukanuba's Longevity Council, a panel of international vet and industry experts including Professor Stuart Carmichael, Dr Penny Watson, Dr Vicki Adams, Professor Steve Dean and David Morgan, which collectively agreed that the secret to healthy ageing in canines is a careful balance of nutrition, good husbandry and effective veterinary care.
Professor Steve Dean, Former Chairman of the UK Kennel Club said: "Nutrition is a major contributor to the health of dogs in the long term, of course it isn’t the only contributor; good husbandry and good veterinary care are the other major pillars for health and longevity. The correct nutrition has a big part to play in maintaining dog health throughout its entire life, which we’ve found out from the Eukanuba Long Life Observation, can be a lot longer than we have previously expected. We’ve always assumed that Labradors will live 12 years if we’re lucky, but now we have a whole new target to aim for…16 and 17 years. It is quite phenomenal."
Dr Penny Watson, Senior Lecturer in Small Animal Medicine, Queen’s Veterinary School Hospital, University of Cambridge said: "Vets as a profession are very good at treating diseases in animals, but perhaps slightly less good at giving preventative advice to pet owners about healthy lifestyles. As vets, we should be thinking all through an animals life cycle, from puppy to geriatric, about the preventative aspects, such as good diet, maintaining the right body condition score and other aspects including dental care, rather than just looking disease and treating it."
David Morgan, Eukanuba’s Senior Scientific Communications Manager said: "The hope is that we can take the message that it’s not only about nutrition but what we call appropriate care, which is veterinary care and husbandry, looking after the dogs in a responsible way. Because, yes we have some great observations and we are starting now with Dr Vicki Adams to break down into more detail what we’ve actually seen in the Eukanuba Labradors and what recommendations we can give in the future so that all dogs can have that longer, healthy and more vibrant lives."
Reference
The RCVS Disciplinary Committee has severely reprimanded and warned as to his future conduct a veterinary surgeon who failed to make sufficient enquiries about the location or condition of a cat; unreasonably refused to provide it with first aid and pain relief; and failed to provide it with adequate 24-hour emergency care.
Following a three-day hearing, the Committee found Marcus Kutschera, of South London Emergency Veterinary Centre, Streatham, guilty of serious professional misconduct in relation to events on 16 May 2011. Mr Kutschera was Clinical Director of the practice, which provided out-of-hours emergency services to several London veterinary practices. At about 1.45am, the practice received two telephone calls from a representative of a registered charity about a cat, which the caller considered should be seen by a veterinary surgeon as soon as possible. The charity was itself a client of one of the practices whose out-of-hours emergency services were provided by the South London Emergency Veterinary Centre. The cat was later euthanased by the RSPCA.
After listening to a recording of a telephone call between a representative of the charity and Mr Kutschera, during which Mr Kutschera failed to ask about either the condition or location of the cat, the Committee was in no doubt that the caller believed Mr Kutschera would not see the cat unless he was able to pay when it was presented. The Committee said that, once the telephone call had been received, the primary responsibility of the veterinary surgeon was the welfare of the animal, and Mr Kutschera had no good reason not to see the cat or to follow the procedures set out in the Guide to Professional Conduct 2010. If he had made proper inquiries, he would have been able to make a provisional diagnosis that the cat was likely to be euthanased. Mr Kutschera was guilty of unreasonably refusing to provide first aid and/or pain relief to the animal, and of failing to provide adequate 24-hour emergency care.
The Committee concluded that Mr Kutschera's conduct fell far short of that to be expected of a veterinary surgeon. Although he did recommend that the cat should be taken to the RSPCA, his primary concern was the ability of the client to make a payment on presentation of the cat, and not the animal's welfare. He had a responsibility for ensuring that proper emergency cover was provided.
In mitigation, the Committee noted that the event was a single, short telephone call between Mr Kutschera and the client in the early hours of the morning, and there was no evidence to suggest similar behaviour on his part on other occasions. Mr Kutschera accepted that he made no inquiries into the cat's condition or location, and the Committee accepted that he had shown some insight into what went badly wrong. He said that he had subsequently changed his practice when speaking to clients on the telephone. The Committee also took account of the impact on Mr Kutschera of the case hanging over him since the complaint was made in August 2011 and, as the cost of the Disciplinary Committee inquiry was not covered by his professional indemnity insurance, he had taken on a substantial financial commitment to pay for legal representation.
Professor Peter Lees, chairing and speaking on behalf of the Committee said: "The primary purpose of the sanction is not to punish but to protect the welfare of animals, maintain public confidence in the profession and uphold proper standards of conduct. Whilst there are undoubted financial issues that can arise in the operation of an out-of-hours service, the primary responsibility of the veterinary surgeon is for the welfare of the animal."
The Committee recommended that Mr Kutschera undertake, within 12 months, continuing professional development training, with a particular emphasis on animal welfare, ethics and client care, in the context of providing out-of-hours services. It imposed on Mr Kutschera the sanction of a severe reprimand and a warning as to his future conduct.
Davies says the new treatment is appropriate for dogs with severe diffuse elbow dysplasia, where cartilage wear results in bone rubbing against bone, called medial compartment disease (MCD). In these cases, Davies says that the prognosis is typically poor but now CUE is providing a promising alternative surgical option when arthroscopic and non-surgical options have failed.
The surgery involves partial resurfacing of the elbow joint. By focusing on the specific area of disease in the medial compartment, the CUE implant provides a less invasive bone-sparing option for resurfacing the bone-on-bone medial compartment while preserving the dog’s own good cartilage in the lateral compartment. Davies says that in most dogs, the technique significantly improves the pain and lameness that was caused by bone-on-bone grinding.
Unlike total elbow replacements, CUE does not require major bone cutting. On average, recovery tends to be significantly faster with progressive improvement peaking six months after surgery.
Mike Farrell, EBVS European and RCVS Specialist in Small Animal Surgery (Orthopaedics) at Davies recently performed a successful CUE procedure on Rubee, an 11-year-old Labradoodle diagnosed with severe MCD. At the recheck, six weeks after surgery Mike said: "Rubee’s early response to CUE has been nothing short of astonishing. I would have been pleased if she had made the improvement seen today after six months rather than six weeks."
Louise Clark Head of Anaesthesia and the Pain Clinic at Davies Veterinary Specialists continued: "CUE potentially provides a surgical alternative for what is currently an incredibly frustrating condition to manage and one that causes animals a lot of pain, and owners a great deal of angst.
"Arguably it is an ethically robust procedure because it can dramatically reduce patient pain with a relatively well defined risk of complications in a patient cohort that is otherwise at risk of euthanasia because of elbow disease."
For more information, visit: https://vetspecialists.co.uk/services/orthopaedics/
Staffies were by far the most commonly stolen animal, accounting for 25.7% of all reported dogs thefts in the UK between 2017 and 2021.
Meanwhile, Devon and Cornwall had the highest number of pet thefts: 140.6 per 100,000 people.
Northumbria came second, with 61.5 pet thefts per 100,000 people, and Lancashire third (52.9 per 100,000).
On the other end of the scale, one breed that was less likely to be stolen was the pug (4.5%), although that's perhaps not surprising: after all, who'd want to steal an animal whose face you can't differentiate from its backside?
The safest animal in the country is probably an Akita (1.9%) living in Surrey (6.8 pet thefts per 100,000 people).
Full report: https://www.adt.co.uk/blog/the-adt-pet-theft-report
The Government has announced that from 6 April 2016 all dogs will be required to have a microchip.
This will give owners 3 years to comply with new legislation being drafted by Defra.
According to Defra, 100,000 dogs are dumped or lost each year at a cost of £57 million to the taxpayer and welfare charities. Only 60% of the 8 million dogs in the UK are currently chipped.
Making microchipping compulsory is intended to help reunite owners with lost or stolen pets, relieve the burden on animal charities and local authorities and protect the welfare of dogs by promoting responsible dog ownership.
Owners will be able to get their dog microchipped free at any of the 18 Dogs Trust centres around the UK, and free microchips will be offered by Dogs Trust to local authorities, housing associations and veterinary surgeries. In addition Battersea Dogs and Cats Home has announced that free microchipping will be offered at its three centres, and the Blue Cross will also offer free microchipping to dogs and cats at its 16 hospitals and centres across England.
Veterinary associations have hailed the introduction of compulsory microchipping for all dogs in England as a giant leap forward for dogs and their owners. BVA President Peter Jones said: "The introduction of compulsory microchipping is a giant leap for dogs and their owners and is something that vets have long campaigned for. Microchipping is a safe and effective way to link dogs to their owners and is an essential part of responsible ownership."
The Government also announced plans to extend the scope of the Dangerous Dogs Act to private places and to allow police to decide if dogs seized under the Act can stay with their owners until the outcome of the court case, removing the need for these dogs to be kennelled. Both of these measures were supported by BVA and BSAVA in joint responses to the Defra consultation.
Virbac has launched the UK's first blood test for BPH (benign prostatic hyperplasia) which, according to the company, will provide practices with a significant opportunity to improve the prognosis for many of the UK's male dog population that suffer from the condition but go undetected.
Odelis CPSE is the first ELISA test to screen, diagnose and monitor BPH. Virbac Product Manager Chris Geddes MRCVS believes that the test is an important step forward in the diagnosis of the condition: "Not only does Odelis CPSE provide a simple and reliable alternative to rectal palpation, it will also give an objective measure of the degree of BPH present."
According to Chris, although BPH affects over 80% of entire male dogs over five years old, many go undiagnosed until the condition is advanced and symptoms become apparent. "Whilst regular screening is recommended in elderly dogs, rectal palpation is not a particularly popular process to carry out routinely without the presence of symptoms.
"We know that currently diagnosis of BPH falls well below the incidence, however this new test means that practitioners can now routinely monitor 'at-risk' dogs, e.g. stud males, elderly dogs, and those with a previous history of BPH. Bloods can be taken at practice visits, or routinely at vaccination boosters or annual health checks for example. So the test is not only good for animal welfare, it's a great business opportunity too".
There are three labs in the UK selected to carry out the test: Biobest; Carmichael Torrance; and Nationwide Laboratories.
Information is being mailed to all practices. Your first test free, and all positive test results recorded up to 31st October will receive a 'buy one get one free' promotion for Ypozane (osaterone acetate), the first-line treatment for BPH.
Alternatively, contact your local Virbac territory manager, or call Virbac on 01359 243243.
In the week that Prince Charles has become embroiled in another row about the use of homeopathy in the NHS, British veterinary surgeons have denounced its use for the treatment of pets and other animals.
In a survey of veterinary surgeons carried out on this website, in which 460 members took part and the preliminary results of which are announced today, an overwhelming 83% said that there are no medical conditions for which homeopathy could be an effective treatment in animals. This figure included the 6.3% of participants who practice veterinary homeopathy themselves, without whom the figure would be even higher.
More specifically, when asked how they would best describe veterinary homeopathy, 4.5% said 'A reliably effective form of veterinary medicine', 8.7% said 'an occasionally effective form of veterinary medicine, 9.5% said: 'a rarely effective form of veterinary medicine, and 77.3% said: 'An ineffective form of veterinary medicine'.
The survey was carried with Alex Gough MA VetMB CertSAM CertVC PGCert MRCVS, Head of Medicine Referrals at Bath Veterinary Group.
So strongly did veterinary surgeons feel about the matter, 78.4% felt that their colleagues should not be allowed to practice homeopathy under their professional title of MRCVS. 73% said that whilst they are still allowed to do so, pet owners should be asked to sign a disclaimer that they understand that in trials, homeopathy has been shown to be ineffective.
However despite the almost universal denunciation of veterinary homeopathy within the profession, when it comes to directing their clients, it seems that many veterinary surgeons do not have quite the same courage of their convictions. Asked what would be the most appropriate response when asked by a client to refer an animal for homeopathic treatment, only 24% of vets said they would explain that homeopathy does not work and recommend the client does not self-refer for homeopathic treatment. 17.5% said they would explain that homeopathy does not work and advise the client to self-refer. 34% said that they would explain that homeopathy doesn't work and refer anyway, and 24% said they would just refer the case.
Buprelieve is a 0.3mg/ml buprenorphine solution for injection, licensed for post-operative analgesia and to potentiate the sedative effects of other centrally-acting agents in dogs and horses. It can be administered by intramuscular or intravenous injection to dogs and cats and by intravenous injection to horses and is available in 10ml multi-dose glass vials.
Dr Rich Irvine BVSc MRCVS, veterinary services manager at Jurox (UK) Limited said: "We are delighted to be extending our range of products with the launch of Buprelieve which will provide veterinary practices with effective and economical analgesia.
"The launch of Buprelieve will be supported by our highly qualified team of veterinary surgeons who aim to deliver top quality help, advice and assistance for clinics wishing to perform best practice anaesthesia across all patient groups."
Jurox says it has been listening to the concerns of veterinary surgeons who say they want high quality generic medicines at affordable prices along with transparency as to what they are paying for each vial. As a result, the company says it is launching Buprelieve at a very affordable list price with a simple and generous introductory offer or rebate.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "Jurox prides itself on providing customers with a range of high quality medicines and we believe the launch of Buprelieve will also satisfy vets’ increasing requests for competitively priced products. We understand that providing high quality pain relief is critical and Buprelieve helps vets deliver the care they demand for their patients."
For more information, contact your local Jurox technical advisor, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
The survey follows the launch last year of a new feature on VetSurgeon Jobs and VetNurse Jobs which allows employers to highlight the salary and benefits they offer. Specifically, the system allows practices to display a 'minimum offer', described to the job seeker as the starting point for a discussion, or a salary range.
Still, currently only 10% of job adverts on VetSurgeon.org and 16% on VetNurse.co.uk include the salary, despite some evidence that broadly speaking, advertising a salary can improve response rates.
But do veterinary job seekers want to see the salary advertised, and if so, how much of a different could it make? These are questions this survey seeks to answer.
My guess is that it may be more important to veterinary nurses than veterinary surgeons, because there is probably a greater variability in salaries amongst nurses, and more jobs where you'd struggle to pay the mortgage.
It'll be interesting to see.
To take part in the survey, which is completely anonymous, visit: https://www.surveygizmo.com/s3/5110214/Should-veterinary-salaries-be-advertised. It's 4 quick fire questions which should take you less than a minute.
A test by the Australian Racing Forensic Laboratory (ARFL) of samples from a newly prepared batch of Bova’s 100mg/ml injectable omeprazole formulation did not detect testosterone, and Racing New South Wales has now released a statement that the product can continue to be used in racehorses following the guidance of Australian Commonwealth and State legislation.
Nick Bova, managing director of Bova UK, said: "Traces of testosterone in the previous batch were less than one millionth of the internationally accepted standard for impurities.
"Independent experts confirmed that there could be no adverse effects on equine health or equestrian sport, however, we have taken steps to identify and completely eliminate the excipient ingredient that contained traces of testosterone."
Nick added: "Bova can confirm that new batches of this product will not contain the previous trace levels of testosterone and therefore Bova are confident there will be no antidoping issues, no matter what the equestrian pursuit is."
The buy-out was led by Professor Nick Bacon, Clinical Director, Dr Laurent Findji, Senior Clinician, Dr Jonathan Bray and Dr Gerard McLauchlan, who will collectively take the hospital forward with the financial backing of a small team of external investors.
Professor Noel Fitzpatrick will continue to lead Fitzpatrick Referrals Orthopaedics and Neurology and Fitzpatrick Referrals Institute for the Restoration of Skeletal Tissue which are both based in Eashing, Surrey.
Fitzpatrick Referrals Oncology and Soft Tissue is rebranding as AURA Veterinary, continuing to focus on animal oncology, soft tissue surgery, interventional radiology and internal medicine.
Under the new management team, AURA Veterinary says it has plans to invest in its team, equipment, scientific innovation and research.
Noel said: “I am proud of everything and everyone who has been part of the journey over the last seven years.
"It is a world-class hospital with an unrivalled team and the foundation we have built together is incredible.
"The time is now right for the team to embark on the next part of their journey - allowing me to also go forward and focus my passion, energy and time at Fitzpatrick Referrals Orthopaedics and Neurology and lead that team into its exciting new phase.”
Nick Bacon, Clinical Director, said: “It was a wonderful opportunity to be involved with a hospital like this from the very beginning, and it’s exciting to be part of its new chapter.
"Laurent and I are hugely grateful to Noel for his vision in creating the hospital, which is unparalleled in the level of care, skill and innovation our team can provide for our patients.
"We look forward to the growth and success of AURA Veterinary.”
Photo: Dr Gerard McLauchlan (standing, back left, in darker scrubs), Professor Nick Bacon, Clinical Director (sitting, front left), Dr Jonathan Bray, (sitting, right), Dr Laurent Findji, Senior Clinician (standing, far right)
Davies says its Cardiac Electrophysiology Laboratory, headed by Pedro Oliveira (pictured right), is one of only four centres in the world to perform the procedure, and it has usually required human medical support. The fact that they've been able to operate independently means the procedure should now start to become more readily available.
The procedure involves introducing special catheters via peripheral veins into the heart, where they are used to record the electrical activity of the heart muscle, thereby allowing the identification of the source and mechanism of cardiac arrhythmias.
Once the abnormal tissue is found, it is destroyed using intense localised energy delivered by another specialised catheter: radiocatheter ablation.
This technique is common in human medicine but very rare in veterinary medicine because of the level of specialisation needed.
In the past, the cardiology team at Davies needed the support of a consultant and a cardiac physiologist from the human field to help carry out the surgery. Having now done it unaided, Pedro is confident that in time Davies will be able to help considerably more patients, promptly after diagnosis.
Pedro said: "In three years we have treated one cat and 19 dogs. Several cases did not survive long enough for surgery despite a waiting time of only a few days to up to two weeks from referral to the procedure. Most of these dogs were puppies. This is incredibly frustrating as if performed early these procedures are curative for most patients."
Davies says that to date it has had a procedural success rate of 100%, with recurrence of the arrhythmia in just one dog. The remaining dogs were cured from their arrhythmias and recovered fully except for two dogs that had sustained too much heart muscle damage and continued to suffer from congestive heart failure.
Pedro added: "Hopefully in the future severe muscle damage can be avoided by early referral when the arrhythmia is detected. If you diagnose a cardiac arrhythmia, especially supraventricular tachycardia, please consider this treatment option because it is very likely to be curative."
The Davies cardiology team can be contacted at cardiology@vetspecialists.co.uk.
Incidentally, Pedro has also co-authored (with Ruth Willis and Antonia Mavropoulou) a new book on electrocardiography. Guide to Canine and Feline Electrocardiography will be published in September 2018 and is available for pre-order on Amazon now, priced at £89.99.
Dr Berwyn Clarke, CEO of PBD Biotech, which developed the bacteriophage-based detection method, says this is significant step forward: "In situations where a farm has had an ongoing chronic bovine TB problem, APHA’s protocol offers a promising new approach to controlling the infection.
"Actiphage is now included within a series of measures that farmers can use in conjunction with their vet and with specific APHA approval as a means to improving their disease management strategy.
"For many farms that have been struggling for years it provides the first step to becoming TB free. This move by the APHA is a really positive step towards tackling this devastating disease."
Much of this new strategy, as part of a private TB eradication plan, has been driven by the success of Devon-based vet Dick Sibley, who incorporated Actiphage into a disease management strategy last Autumn to help clear a dairy herd that had been stricken with TB since 2012.
Dick said: "The approach of directly measuring the presence of live bacteria in the blood in just six hours is a totally different but complementary measurement to other technologies and has enabled enhanced testing, early detection and containment of the infected animals.
"We don’t have all of the answers yet, but it’s about predicting, preventing and managing what we can – and Actiphage has contributed greatly to the outcome we’ve been after for so long."
The Exceptional private use of non-validated tests for TB on cattle in England protocol enables any private veterinary surgeon to request APHA permission for exceptional use of Actiphage and the other non-validated tests, subject to certain criteria that include herd supplementary interferon-γ (IFN- γ) testing, discussions with the APHA Case Vet and the farmer’s written consent.
Berwyn added: "Actiphage is unique in directly detecting live mycobacteria in blood or milk, and it can also distinguish between a vaccinated and an infected animal - paving the way for new types of disease control when vaccines become available in the future.
"We are working with international governments, and the test is being trialled on bovine, ovine as well as exotic species, but we appreciate it is new to the UK market so we’re keen to answer any queries vets or farmers may have."
The new test will be profiled in the Innovation Hub at the Royal Norfolk Agricultural Show next month (27 & 28 June).
PBD Biotech says Actiphage will require further testing before it is officially approved for standard veterinary use in the UK, however under the APHA protocol it is now permitted for private use where herds have experienced persistent breakdowns and this will contribute to the evidence-base required for official validation by the OIE and acceptance by APHA.
Within this protocol, APHA has outlined a number of other non-validated tests that may be proposed for exceptional use in cattle herds with chronic breakdowns, including: the Actiphage assay, developed by PBD Biotech and Nottingham University; the Enferplex TB serological test, produced by Enfer Laboratories Ireland and approved in GB for use in camelids; and the Polymerase Chain Reaction (PCR) testing of faecal samples. APHA says this is not an exhaustive list and that the protocol covers any current or future non-validated tests for bovine TB.
The comparative intradermal tuberculin skin test and the IFN- γ blood test remain the only ante mortem tests currently approved for the statutory cattle TB testing programme in Great Britain.
The full Exceptional private use of non-validated tests for TB on cattle in England is available on the APHA Vet Gateway: apha.defra.gov.uk/vet-gateway/non-valid-tb-testing
The announcement came in the form of a written statement by the then Home Secretary Sajid Javid to the House of Commons on 23rd July, which said: "The Government is happy to accept all of the MAC’s recommendations on the composition of the SOL and the necessary amendments will be made in the Autumn Immigration Rules changes."
Being on the shortage occupation list means that employers do not need to advertise jobs for veterinary surgeons in the UK for 28 days before advertising abroad (the Resident Labour Market Test). In addition, there are lower visa fees and it provides exemption from the minimum income threshold.
RCVS President Niall Connell said: "Both the Royal College of Veterinary Surgeons and the British Veterinary Association worked together to ensure this outcome, which will see a lowering of the immigration barriers, for example, in terms of visa requirements, for overseas veterinary surgeons who wish to live and work in the UK.
"We also considered this a vital piece of preparation for the UK leaving the EU, as around half of those registering as veterinary surgeons with the RCVS in a given year are non-UK EU nationals and we would not want to see this vital supply of veterinary talent immediately dry up should ‘freedom of movement’ end when the UK leaves the EU.
"We thank Mr Javid for accepting the Committee’s proposals and congratulate his successor Priti Patel on her appointment and look forward to the decision being implemented. The new Prime Minister pledged on the steps of Downing Street to do more to promote the welfare of animals, and having veterinary surgeons on the Shortage Occupation List will help in our mission to uphold animal health and welfare and ensure that vital veterinary work can continue to get done, whatever happens with the relationship between the UK and the EU."
The main aim of the campaign is to persuade anyone thinking of getting a puppy that they should always see the animal at least once whilst it is still dependent on its mother, before they buy. That way, they'll be able to reassure themselves that they have seen the real bitch and the environment in which the puppy was bred. It will also help prevent impulse purchases.
In addition, the campaign aims to raise awareness in the veterinary profession, so that veterinary surgeons are giving this same advice to their clients.
To that end, the campaign highlights the RSPCA 'Sold a pup' report which showed that over 400,000 pups are bred for the UK market each year by unlicensed establishments, and imports from Europe have increased to an estimated 30,000 in 2015, following the change in the PETS scheme in 2012.
The campaigners say that many of these puppies are bred in truly awful conditions, often with little or no human contact, before being taken taken from their mothers too early and transported often hundreds or thousands of miles to be sold as 'family' pets. Many will need veterinary care to deal with infections, inherited issues and behavioural problems.
The campaign faces a big challenge. In the Kennel Club PAW survey 2014, 41% of people who bought a puppy didn't see the bitch and 51% didn't see the environment where the litter was bred.
To spread the word, veterinary surgeons, veterinary nurses and pet owners are being asked to take a pouting selfie with their dog and post it on social networks like Facebook, with the hashtags #PoutForPuppies #SeeThemSuckling, linking to the campaign website: https://seethemsuckling.com
Fynadyne had been removed from sale last year after the Veterinary Medicines Directorate suspended the sale of any medicinal products containing the excipient diethanolamine (DEA), following advice to the European Medicines Agency that it could pose a risk to human health.
Finadyne 50mg/ml Solution for Injection is indicated for the alleviation of acute inflammation and pain in both cattle and pigs. It is also indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders and colic in horses.
The reformulated product has a shelf life of three years and is now available from wholesalers in 50ml and 100ml vials.
For further information, contact your MSD Animal Health account manager.
Credelio Plus is a palatable, chewy, monthly tablet which contains milbemycin oxime for the control of the gastrointestinal nematodes: hookworm (L4, immature adult (L5) and adult Ancylostoma caninum), roundworms (L4, immature adult (L5) and adult Toxocara canis and adult Toxascaris leonina) and whipworm (adult Trichuris vulpis). Also for the prevention of angiostrongylosis by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum (lungworm) with monthly administration. Also for the prevention of heartworm disease (Dirofilaria immitis).
Credelio Plus also contains lotilaner for the immediate and persistent treatment of ticks (Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus and I. hexagonus) and flea (Ctenocephalides felis and C. canis) infestations in dogs.
Credelio Plus is licensed for puppies as young as 8 weeks and weighing 1.4 kg or more.
Tina Hunt, General Manager of Elanco UK/Ireland said: "The launch of Credelio Plus represents another exciting evolutionary leap for Elanco’s parasiticide portfolio.”
Cat Henstridge MRCVS, otherwise known as 'Cat the Vet' said: "As a companion animal vet, one of the common challenges I see from pet owners is the need to remember and administer multiple treatments to cover a variety of parasites.
"So a simple, easy-to-remember treatment will be welcomed by my clients who need a combination solution to protect their dogs from ticks, fleas and worms.”
To mark the launch of Credelio Plus, Elanco is inviting vets and nurses to register for an online event at which the astronaut Major Tim Peake will talk about the lessons he’s learnt about leadership and teamwork, performing in high-pressured environments and the future of medicine and science. He'll be followed by Cat Henstridge, who will give a presentation about the power of wider veterinary teams working ‘better together’ to support each other, and how practices can start to reconnect with their clients following lockdown.
Lepha McCartan, BVetMed MRCVS, Veterinary Technical Consultant, Elanco Animal Health, will also speak about Elanco’s ongoing work within the parasite space. There will also be a live Q&A where attendees can put questions to the panel.
To sign up for the launch event, visit https://www.myelanco.co.uk/brand/credelio-plus-launch-registration
Nat Whitley, clinical director at Davies Veterinary Services, said: "We are delighted to become part of the Linnaeus Group. We pride ourselves on delivering excellent service, so when the opportunity arose to become part of such a forward-thinking, impressive group it was a great match."
Emma Barnes, Linnaeus Group operations director, said: "We are very pleased to welcome Davies Veterinary Specialists to the Linnaeus family and look forward to combining their excellent work and care with our expertise, experience and support.
"We carefully select our partners in the Group to ensure the delivery of the highest quality of care and service across the entire business, which is why we are so pleased to have the Davies team on board."
The data shows a stable population of 12m pets, as follows:
There were also:
The survey also provides an interesting point at which to note some historical trends. Whilst cats and dogs have always been the most popular pets, 50 years ago it was budgerigars that held third place. Since then, the dog population has grown 76% and the cat population has grown 63%, whilst rabbits have moved into third place.
Nicole Paley, PFMA Deputy Chief Executive, said: "Almost half of UK households are benefitting from pet ownership and whilst cats and dogs continue to be the most popular pets, rabbits came in at third place followed by indoor birds, guinea pigs and domestic fowl.
"A key role of PFMA is to provide educational resources on how to ensure the full range of pets get the right nutrition and we really value the role of vets and vet nurses being at the front line to pass this information on.
"At PFMA we are here to support the veterinary profession and we have a series of factsheets on popular feeding topics such as ‘Do all small mammals eat the same food’ and ‘Nutrition for indoor birds. Our pet companions fill our lives with love and joy and in return, it’s important we provide the care they need. "
For more information, visit www.pfma.org.uk/statistics